[go: up one dir, main page]

MX2007005199A - Indolizinas sustituidas y derivados como agentes del sistema nervioso central. - Google Patents

Indolizinas sustituidas y derivados como agentes del sistema nervioso central.

Info

Publication number
MX2007005199A
MX2007005199A MX2007005199A MX2007005199A MX2007005199A MX 2007005199 A MX2007005199 A MX 2007005199A MX 2007005199 A MX2007005199 A MX 2007005199A MX 2007005199 A MX2007005199 A MX 2007005199A MX 2007005199 A MX2007005199 A MX 2007005199A
Authority
MX
Mexico
Prior art keywords
derivatives
cns agents
compounds
indolizines
substituted
Prior art date
Application number
MX2007005199A
Other languages
English (en)
Inventor
Robert Lewis Vogel
Annmarie Louise Sabb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007005199A publication Critical patent/MX2007005199A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos de la formula (I) de sales farmaceuticamente aceptables de los mismos: formula (I)., los cuales son agonistas o agonistas parciales del subtipo 2C de receptores de serotonina cerebral. Los compuestos, y composiciones que contienen los compuestos, pueden utilizarse para tratar una variedad de trastornos del sistema nervioso central, tal como esquizofrenia.
MX2007005199A 2004-11-01 2005-10-27 Indolizinas sustituidas y derivados como agentes del sistema nervioso central. MX2007005199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62442304P 2004-11-01 2004-11-01
PCT/US2005/038702 WO2006050007A2 (en) 2004-11-01 2005-10-27 Substituted indolizines and derivatives as cns agents

Publications (1)

Publication Number Publication Date
MX2007005199A true MX2007005199A (es) 2007-05-11

Family

ID=36177318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005199A MX2007005199A (es) 2004-11-01 2005-10-27 Indolizinas sustituidas y derivados como agentes del sistema nervioso central.

Country Status (9)

Country Link
US (1) US7608626B2 (es)
EP (1) EP1807427A2 (es)
JP (1) JP2008518917A (es)
CN (1) CN101094852A (es)
AU (1) AU2005302559A1 (es)
BR (1) BRPI0517955A (es)
CA (1) CA2585967A1 (es)
MX (1) MX2007005199A (es)
WO (1) WO2006050007A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
JP5638612B2 (ja) * 2009-09-10 2014-12-10 エルジー・ケム・リミテッド 新規な複素環誘導体およびこれを用いた有機発光素子
FR2953716B1 (fr) * 2009-12-16 2015-03-27 Oreal Kit de formulation d'un produit cosmetique
FR2961097B1 (fr) * 2010-06-09 2012-07-13 Oreal Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
FR2961095B1 (fr) * 2010-06-09 2012-06-15 Oreal Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
CN102295644B (zh) * 2011-05-25 2012-12-05 同济大学 一种合成1-卤-2-芳基中氮茚类化合物的方法
CN102603735B (zh) * 2012-02-06 2014-07-16 浙江新和成股份有限公司 一种c-2芳基化吲哚嗪化合物的制备方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN112010777B (zh) * 2020-08-20 2022-10-11 浙江大学衢州研究院 于管道化反应器内进行的酰胺连续化制备腈的方法
CA3236339A1 (en) * 2021-11-03 2023-05-11 Matthew BAGGOTT Indolizine compounds for the treatment of mental disorders or mental enhancement

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416724D0 (en) 1984-06-30 1984-08-01 Sorbio Sa Lab Active compounds
DE3677101D1 (de) 1985-06-28 1991-02-28 Beecham Wuelfing Gmbh & Co Kg Tetrahydropyrido-(1,2-a)-indolderivate, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
EP0252643A1 (en) 1986-07-01 1988-01-13 BEECHAM - WUELFING GmbH & Co. KG Pyrido[1,2-a]indole derivatives, process for their preparation and pharmaceutical compounds containing them
CA1329597C (en) 1986-12-22 1994-05-17 Dagmar Hoeltje Derivatives of tetrahydropyrido[1,2-a]indole
WO1992021678A1 (en) 1991-06-07 1992-12-10 Smithkline Beecham Corporation LIPOXYGENASE INHIBITING PYRROLO [1,2a]INDOLE COMPOUNDS
GB9316195D0 (en) 1993-08-05 1993-09-22 Smithkline Beecham Plc Pharmaceuticals
GB9318790D0 (en) 1993-09-10 1993-10-27 Fujisawa Pharmaceutical Co Heterocyclic derivatives
AU7000696A (en) 1995-09-22 1997-04-09 Fujisawa Pharmaceutical Co., Ltd. Novel processes for producing pyridoindole derivatives
IL129484A0 (en) 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
CA2338866A1 (en) 1998-07-30 2000-02-10 Japan Tobacco Inc. Disubstituted maleimide compound and pharmaceutical use thereof
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
EP1149078B1 (en) 1998-12-11 2006-03-08 Virginia Commonwealth University Selective 5-ht 6 receptor ligands
DE19907701A1 (de) 1999-02-23 2000-08-24 Bayer Ag Mit tricyclischen Indolen substituierte Oxazolidinone
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環系化合物
US7041675B2 (en) * 2000-02-01 2006-05-09 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as PARP inhibitors
FR2805539B1 (fr) * 2000-02-25 2005-06-10 Oreal Compositions de teinture des fibres keratiniques contenant des derives d'indolizine et procede de teinture
TR200400354T4 (tr) 2000-03-31 2004-04-21 Ortho-Mcneil Pharmaceutical, Inc. Fenil ikameli indolizin türevleri ve bunların histamin H3 ligandları olarak kullanımı
ES2291374T3 (es) 2000-12-27 2008-03-01 F. Hoffmann-La Roche Ag Derivados de indol y su empleo como ligandos receptores de 5-ht2b y 5-ht2c.

Also Published As

Publication number Publication date
AU2005302559A1 (en) 2006-05-11
WO2006050007A2 (en) 2006-05-11
EP1807427A2 (en) 2007-07-18
CN101094852A (zh) 2007-12-26
BRPI0517955A (pt) 2008-10-21
WO2006050007A3 (en) 2006-08-03
CA2585967A1 (en) 2006-05-11
JP2008518917A (ja) 2008-06-05
US20060094752A1 (en) 2006-05-04
US7608626B2 (en) 2009-10-27

Similar Documents

Publication Publication Date Title
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
TW200716595A (en) Chromane and chromene derivatives and uses thereof
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
MX2007004699A (es) Derivados de indol y bencimidazol.
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
TNSN05328A1 (en) (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
MX2010001486A (es) Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
MX2007005199A (es) Indolizinas sustituidas y derivados como agentes del sistema nervioso central.
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
WO2008020306A3 (en) Isoindole derivatives
PL1807434T3 (pl) Tienopirydyny jako allosteryczne środki wzmacniające receptor M4 muskarynowy
NO20080033L (no) Kinolinderivater som NK3-antagonister
WO2008052075A3 (en) Benzoxazine derivatives and uses thereof
WO2008052088A8 (en) Chromane derivatives, synthesis thereof, and intermediates thereto
MY148772A (en) Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
WO2008052078A3 (en) Benzoxathiine and benzoxathiole derivatives and uses thereof
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
ATE386738T1 (de) Flavaxat-derivate als muscarin-rezeptor antagonisten